COMPANY PROFILE // THE 014 REPORT
Harmony Biosciences Holdings, Inc.
HRMY (Nasdaq)
Assembled from 2 government sources in 2.6 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber5 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-30: a pattern of leadership change.
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Harmony Biosciences Holdings, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Plymouth Meeting, PA; listed as HRMY (Nasdaq).[source] It reported revenue of $868.5 million for the fiscal year ended 2025-12-31.[source] It has filed 70 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., FMR LLC, VANGUARD PORTFOLIO MANAGEMENT LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 5 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-10-30.[source]
- red0
- amber1
- info0
- BlackRock, Inc.$258.6M
- FMR LLC$130.1M
- VANGUARD PORTFOLIO MANAGEMENT LLC$104.9M
- AMERICAN CENTURY COMPANIES INC$92.5M
- DIMENSIONAL FUND ADVISORS LP$87.1M
- VANGUARD CAPITAL MANAGEMENT LLC$76.6M
- STATE STREET CORP$67.7M
- ARMISTICE CAPITAL, LLC$56.9M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Budur Kumar · CHIEF MEDICAL OFFICER (Officer) · latest Form 4 2026-01-26 · filing · LinkedIn search
- Dayno Jeffrey M. · PRESIDENT, CEO (Director,Officer) · latest Form 4 2026-01-26 · filing · LinkedIn search
- Kapadia Sandip · CHIEF FINANCIAL OFFICER (Officer) · latest Form 4 2026-01-28 · filing · LinkedIn search
- Serafin Andrew · CHIEF STRATEGY OFFICER (Officer) · latest Form 4 2026-01-26 · filing · LinkedIn search
- Zaeske Adam H. · CHIEF COMMERCIAL OFFICER (Officer) · latest Form 4 2026-01-26 · filing · LinkedIn search
- Anastasiou Peter · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Gracias Antonio J. · Director,10% owner · latest Form 4 2025-09-02 · filing · LinkedIn search
- Graf R. Mark · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Philip Ron M · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Sabater Juan A. · Director,10% owner · latest Form 4 2025-09-02 · filing · LinkedIn search
- Sender Gary · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Szyper Linda M · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001802665 | source |
| EIN | 82-2279923 | source |
| Business address (SEC) | 630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Passage BIO, Inc. · Kapadia Sandip
- SIGNET JEWELERS LTD · Graf R. Mark
- Marqeta, Inc. · Graf R. Mark
- iBio, Inc. · Sender Gary
- Schrodinger, Inc. · Sender Gary
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-10-30 officer change 8-K/A items 5.02,9.01 · SEC EDGAR
- 2026-10-13 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-09-18 filing 144 · SEC EDGAR
- 2026-09-17 filing 144 · SEC EDGAR
- 2026-09-16 filing 144 · SEC EDGAR
- 2026-09-08 filing 144 · SEC EDGAR
- 2026-09-04 filing 144 · SEC EDGAR
- 2026-08-07 filing 144 · SEC EDGAR
- 2026-08-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-04 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-07-16 officer change 8-K items 2.02,5.02,7.01,9.01 · SEC EDGAR
- 2026-07-02 filing 144 · SEC EDGAR
- 2026-06-30 filing 144 · SEC EDGAR
- 2026-06-26 filing 144 · SEC EDGAR
- 2026-06-24 filing 144 · SEC EDGAR
- 2026-06-09 filing 144 · SEC EDGAR
- 2026-06-05 filing 144 · SEC EDGAR
- 2026-06-04 filing 144 · SEC EDGAR
- 2026-05-14 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-08 filing 144 · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,7.01,9.01 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-14 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-04-03 filing ARS · SEC EDGAR
- 2026-04-03 filing DEFA14A · SEC EDGAR
- 2026-04-03 filing Proxy statement · SEC EDGAR
- 2026-04-02 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-02-24 filing Annual report (10-K) · SEC EDGAR
165 earlier entries
- 2026-02-24 filing 8-K items 2.02,7.01,9.01
- 2026-01-26 filing 144
- 2026-01-26 insider First Form 3/4/5 on record for Serafin Andrew (CHIEF STRATEGY OFFICER)
- 2026-01-15 filing 144
- 2026-01-12 filing 8-K items 2.02,7.01,9.01
- 2025-12-17 insider First Form 3/4/5 on record for Dayno Jeffrey M. (PRESIDENT, CEO)
- 2025-12-12 filing 144
- 2025-12-05 filing 144
- 2025-11-21 filing 144
- 2025-11-04 filing Quarterly report (10-Q)
- 2025-11-04 filing 8-K items 2.02,7.01,9.01
- 2025-10-23 filing 8-K items 2.02,9.01
- 2025-09-24 filing 8-K items 7.01,9.01
- 2025-08-15 filing 144
- 2025-08-05 filing Quarterly report (10-Q)
- 2025-08-05 filing 8-K items 2.02,7.01,9.01
- 2025-06-11 filing 8-K items 7.01,9.01
- 2025-06-10 filing 144
- 2025-06-05 filing 8-K items 8.01,9.01
- 2025-05-19 filing 144
- 2025-05-16 filing 144
- 2025-05-16 insider First Form 3/4/5 on record for Anastasiou Peter (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Gracias Antonio J. (Director,10% owner)
- 2025-05-16 insider First Form 3/4/5 on record for Graf R. Mark (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Sabater Juan A. (Director,10% owner)
- 2025-05-16 insider First Form 3/4/5 on record for Sender Gary (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Szyper Linda M (Director)
- 2025-05-15 filing 8-K items 5.07
- 2025-05-12 filing 144
- 2025-05-09 filing 144
- 2025-05-09 insider First Form 3/4/5 on record for Budur Kumar (CHIEF MEDICAL OFFICER)
- 2025-05-08 filing 144
- 2025-05-07 filing 144
- 2025-05-06 filing Quarterly report (10-Q)
- 2025-05-06 filing 8-K items 2.02,7.01,9.01
- 2025-04-16 insider First Form 3/4/5 on record for Zaeske Adam H. (CHIEF COMMERCIAL OFFICER)
- 2025-04-15 filing UPLOAD
- 2025-04-09 filing CORRESP
- 2025-04-04 filing ARS
- 2025-04-04 filing DEFA14A
- 2025-04-04 filing Proxy statement
- 2025-04-04 insider First Form 3/4/5 on record for Philip Ron M (Director)
- 2025-04-03 officer change 8-K items 5.02,7.01,9.01
- 2025-04-01 filing 144
- 2025-04-01 insider First Form 3/4/5 on record for Kapadia Sandip (CHIEF FINANCIAL OFFICER)
- 2025-03-28 filing UPLOAD
- 2025-03-24 officer change 8-K items 5.02,8.01,9.01
- 2025-03-03 filing 144
- 2025-02-25 filing S-8
- 2025-02-25 filing S-3ASR
- 2025-02-25 filing Annual report (10-K)
- 2025-02-25 filing 8-K items 2.02,7.01,9.01
- 2025-01-27 filing 144
- 2025-01-27 filing 144
- 2025-01-24 filing 144
- 2025-01-21 filing 144
- 2025-01-21 filing 144
- 2025-01-21 filing 144
- 2025-01-13 filing 144
- 2025-01-13 filing 8-K items 2.02,7.01,9.01
- 2024-11-01 filing 8-K items 8.01,9.01
- 2024-10-31 filing 424B7
- 2024-10-29 filing 424B7
- 2024-10-29 filing 144
- 2024-10-29 filing Quarterly report (10-Q)
- 2024-10-29 filing 8-K items 2.02,7.01,9.01
- 2024-10-03 filing 144
- 2024-10-01 filing 144
- 2024-10-01 filing 8-K items 7.01,9.01
- 2024-09-30 filing 144
- 2024-09-27 filing 144
- 2024-08-06 filing 8-K items 2.02,7.01,9.01
- 2024-08-06 filing Quarterly report (10-Q)
- 2024-07-01 officer change 8-K items 5.02,8.01,9.01
- 2024-05-29 filing 8-K items 5.07
- 2024-05-03 officer change 8-K items 5.02,9.01
- 2024-04-30 filing Quarterly report (10-Q)
- 2024-04-30 filing 8-K items 2.02,7.01,9.01
- 2024-04-11 filing ARS
- 2024-04-11 filing 8-K items 1.01,8.01,9.01
- 2024-04-11 filing DEFA14A
- 2024-04-11 filing Proxy statement
- 2024-03-15 filing 144
- 2024-03-08 filing 144
- 2024-02-28 filing 10-K/A
- 2024-02-22 filing S-8
- 2024-02-22 filing Annual report (10-K)
- 2024-02-22 filing 8-K items 2.02,7.01,9.01
- 2024-01-08 filing 8-K items 2.02,9.01
- 2023-12-07 filing 8-K/A items 9.01
- 2023-11-08 officer change 8-K items 5.02,7.01,9.01
- 2023-10-31 filing Quarterly report (10-Q)
- 2023-10-31 filing 8-K items 2.02,7.01,8.01,9.01
- 2023-10-13 filing 8-K items 8.01,9.01
- 2023-10-11 filing SC TO-T/A
- 2023-10-11 filing 8-K items 2.01,7.01,9.01
- 2023-10-05 officer change 8-K items 5.02,9.01
- 2023-10-05 filing SC TO-T/A
- 2023-10-04 filing 8-K items 8.01,9.01
- 2023-09-27 filing SC TO-T/A
- 2023-09-25 filing 8-K items 1.01,9.01
- 2023-09-14 filing SC TO-T/A
- 2023-09-14 filing CORRESP
- 2023-09-14 filing 8-K/A items 1.01,9.01
- 2023-09-13 filing UPLOAD
- 2023-09-12 filing CORRESP
- 2023-08-31 filing UPLOAD
- 2023-08-28 filing SC TO-T
- 2023-08-24 filing SC 13D
- 2023-08-14 filing SC TO-C
- 2023-08-14 filing 8-K items 1.01,7.01,9.01
- 2023-08-14 filing SC TO-C
- 2023-08-01 filing Quarterly report (10-Q)
- 2023-08-01 filing 8-K items 2.02,7.01,8.01,9.01
- 2023-07-27 filing 8-K items 1.01,1.02,7.01,9.01
- 2023-05-31 officer change 8-K/A items 5.02
- 2023-05-26 filing 8-K items 5.07
- 2023-05-02 filing S-8
- 2023-05-02 filing Quarterly report (10-Q)
- 2023-05-02 filing 8-K items 2.02,7.01,9.01
- 2023-04-24 officer change 8-K items 5.02,7.01,9.01
- 2023-04-14 filing ARS
- 2023-04-14 filing DEFA14A
- 2023-04-14 filing Proxy statement
- 2023-03-29 filing 8-K items 8.01,9.01
- 2023-03-10 filing 8-K items 8.01
- 2023-02-21 filing Annual report (10-K)
- 2023-02-21 filing 8-K items 2.02,7.01,9.01
- 2023-01-23 officer change 8-K/A items 5.02,9.01
- 2023-01-23 officer change 8-K items 5.02
- 2023-01-06 officer change 8-K items 5.02,7.01,9.01
- 2022-11-01 filing Quarterly report (10-Q)
- 2022-11-01 filing 8-K items 2.02,7.01,9.01
- 2022-10-03 filing 8-K items 8.01
- 2022-09-28 filing 8-K/A items 5.07
- 2022-08-02 filing Quarterly report (10-Q)
- 2022-08-02 filing 8-K items 2.02,7.01,9.01
- 2022-05-23 filing 8-K items 5.07
- 2022-05-03 filing Quarterly report (10-Q)
- 2022-05-03 filing 8-K items 2.02,7.01,9.01
- 2022-04-08 filing DEFA14A
- 2022-04-08 filing Proxy statement
- 2022-02-28 filing S-8
- 2022-02-28 filing Annual report (10-K)
- 2022-02-28 filing 8-K items 2.02,7.01,9.01
- 2021-11-22 officer change 8-K items 5.02,7.01,9.01
- 2021-11-09 filing 424B5
- 2021-11-09 filing S-3ASR
- 2021-11-09 filing Quarterly report (10-Q)
- 2021-11-09 filing 8-K items 2.02,7.01,9.01
- 2021-08-11 filing 8-K items 2.02,7.01,9.01
- 2021-08-10 filing Quarterly report (10-Q)
- 2021-06-15 officer change 8-K items 5.02
- 2021-05-21 filing 8-K items 5.07
- 2021-05-11 filing Quarterly report (10-Q)
- 2021-05-11 filing 8-K items 2.02,7.01,9.01
- 2021-04-09 filing DEFA14A
- 2021-04-09 filing Proxy statement
- 2021-03-25 filing Annual report (10-K)
- 2021-03-25 filing 8-K items 2.02,7.01,9.01
- 2021-03-15 officer change 8-K items 5.02,9.01
- 2021-03-10 officer change 8-K items 5.02,9.01
- 2021-02-19 filing 8-K items 8.01
- 2020-12-17 filing 8-K items 8.01,9.01
- 2020-12-15 filing 8-K items 8.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-30 (within 30 days) 8-K/A filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-10-13 (older) 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-04 (older) 10-Q filed
- 2026-08-04 (older) 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-16 (older) 8-K filed: Item 2.02 results of operations; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-14 (older) 8-K filed: Item 5.07 shareholder vote
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:HRMY The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1802665 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | HRMY / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 822279923 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001802665 | SEC EDGAR / IRS |
| CUSIP | 413197104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001802665 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $868,453,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 00:27 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $158,687,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 00:27 UTC | Report an error |
| Total assets (at 2025-12-31) | $1,271,631,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 00:27 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $870,218,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 00:27 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $752,502,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 00:27 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
| Business address | 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, PA, 19462 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-21 00:27 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $348,199,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 00:27 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $310,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 00:27 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $163,663,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 00:27 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $5,585,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 00:27 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001104659-26-122390
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $268,917,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
| Net income (loss) | $48,196,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
| Interest expense | $3,060,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
| Cash and cash equivalents | $647,099,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
| Debt due in the next 12 months | $20,000,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
| Debt due in year 2 | $125,000,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122390 | 2026-11-21 00:27 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing 10-Q filed
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-30 Filing 8-K/A filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-10-13 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-04 Filing 10-Q filed
- 2026-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-07-16 Filing 8-K filed: Item 2.02 results of operations; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-14 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-04-14 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-03 Filing ARS filed
- 2026-04-03 Filing DEFA14A filed
- 2026-04-03 Filing DEF 14A filed
- 2026-04-02 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-02-24 Filing 10-K filed
- 2026-02-24 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-01-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-04 Filing 10-Q filed
- 2025-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-10-23 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-09-24 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-08-05 Filing 10-Q filed
- 2025-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-06-11 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02, Results of Operations and Financial Condition
On November 4, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. the 8-K · retrieved 2026-11-21 00:27 UTC - 2026-11-04 8-K Item 7.01, Regulation FD Disclosure
On November 4, 2026, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the… the 8-K · retrieved 2026-11-21 00:27 UTC - 2026-10-13 8-K Item 7.01, Regulation FD Disclosure
On October 12, 2026, the Company issued a press release announcing the leadership transition described in Item 5.02 of this Current Report. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as set forth… the 8-K · retrieved 2026-11-21 00:27 UTC - 2026-08-04 8-K Item 2.02, Results of Operations and Financial Condition
On August 4, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. the 8-K · retrieved 2026-11-21 00:27 UTC - 2026-08-04 8-K Item 7.01, Regulation FD Disclosure
On August 4, 2026, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the… the 8-K · retrieved 2026-11-21 00:27 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $258,582,545 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 2 | FMR LLC | $130,133,520 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $104,878,604 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 4 | AMERICAN CENTURY COMPANIES INC | $92,463,632 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 5 | DIMENSIONAL FUND ADVISORS LP | $87,144,817 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $76,644,980 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 7 | STATE STREET CORP | $67,697,914 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 8 | ARMISTICE CAPITAL, LLC | $56,945,240 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $52,534,476 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
| 10 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $47,789,946 | 2026-06-30 | SEC 13F filing | 2026-11-21 00:27 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1802665.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001802665. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.